We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Chinese Firm Sinovac Biotech Says It Is 99% Sure that Its COVID-19 Vaccine Will Work

By HospiMedica International staff writers
Posted on 01 Jun 2020
Print article
Sinovac Biotech Ltd. (Beijing, China), a biopharmaceutical company, has stated that the company is 99% sure that its COVID-19 vaccine, called CoronaVac, will work.

Sinovac has received approval from government authorities to conduct both Phase I and Phase II human clinical trials of its COVID-19 vaccine in China. The company has made significant process in the development of CoronaVac. The Phase I clinical trial, which evaluated the safety, tolerance, and preliminary immunogenicity of the COVID-19 vaccine, commenced in April. The company recently published preclinical results regarding CoronaVac, noting that the vaccine candidate was safe and provided protection to rhesus macaques (monkeys) through an animal challenge study.

After preliminary observation of the safety profile of CoronaVac in the Phase I study, Sinovac began conducting Phase II trial of its coronavirus vaccine in May that involved more than 1,000 volunteers. The Phase II clinical trial will evaluate the immunogenicity and safety of CoronaVac in a larger population in order to define dosage, regimen and immunization schedule. The company is now in preliminary discussions to hold the Phase III trial of its coronavirus vaccine, with the final part of the process planned to be conducted in the UK.

Sinovac has secured USD 15 million in funding to accelerate its COVID-19 vaccine development and is constructing a commercial vaccine production plant that is expected to manufacture up to 100 million doses of CoronaVac annually. According to a report by Sky News, when Luo Baishan, a researcher at Sinovac, was asked by their reporter whether he thought the vaccine would be successful, he said, "Yes, yes. It must be successful… 99% (sure)."

Related Links:
Sinovac Biotech Ltd.

Print article


Surgical Techniques

view channel
Image: Persona IQ is a first-to-world smart implant that captures key kinematic data metrics (Photo courtesy of Zimmer Biomet)

World’s First Smart Knee Implant Optimizes Patient Monitoring and Recovery After Surgery

A first-to-world smart knee implant utilizes sensor-based technology to allow physicians and care teams to collect patient-specific kinematic data during the course of patient monitoring.... Read more

Patient Care

view channel
Image: The biomolecular film can be picked up with tweezers and placed onto a wound (Photo courtesy of TUM)

Biomolecular Wound Healing Film Adheres to Sensitive Tissue and Releases Active Ingredients

Conventional bandages may be very effective for treating smaller skin abrasions, but things get more difficult when it comes to soft-tissue injuries such as on the tongue or on sensitive surfaces like... Read more

Health IT

view channel
Image: AI can reveal a patient`s heart health (Photo courtesy of Mayo Clinic)

AI Trained for Specific Vocal Biomarkers Could Accurately Predict Coronary Artery Disease

Earlier studies have examined the use of voice analysis for identifying voice markers associated with coronary artery disease (CAD) and heart failure. Other research groups have explored the use of similar... Read more


view channel
Image: The global capsule endoscopy system market is growing at a rapid pace (Photo courtesy of Pexels)

Capsule Endoscopy System Market Driven by Rising Preference for Minimally Invasive Screening Procedure

Capsule endoscopy is generally a non-invasive technique that enables complete examination of the gastrointestinal tract with the use of the disposable and wireless device known as the video capsule.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.